START - South Texas Accelerated Research Therapeutics

START in the News

New Headquarters of START

New cancer treatment center coming in 2008

Leading Oncology Treatment and Research Groups Establishing Comprehensive Cancer Center

Construction is officially under way for the new headquarters of South Texas Oncology and Hematology (STOH) and South Texas Accelerated Research Therapeutics (START). The 120,000-square-foot building will bring together some of the nation’s most accomplished oncologists and researchers and is expected to open at the end of 2008.

2009 | 2008 | 2007

Construction of new headquarters.

Date	Title
12/24/08	Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
11/20/08	START cancer center nearing the finish
10/29/08	Novel Dosing Strategy for IMGN242 in Gastric Cancer Based on Circulating-Antigen Plasma Levels: EORTC-NCI-AACR
10/23/08	SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
10/03/08	Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
10/03/08	Leading US Phase I Cancer Center Opens Site In Madrid, Spain - START Center For Cancer Care
10/03/08	SA Cancer Research Group Goes Global
09/28/08	New cancer-fighting drug shows promise in study
09/09/08	START creates S.A. tumor bank (Article)
09/09/08	START creates S.A. tumor bank (Video)
09/08/08	FivePrime Initiates Phase I Clinical Trial of FP-1039 in Patients With Advanced Cancers
09/02/08	Cancer facilities in S.A. seen as cutting-edge (Article)
09/02/08	Cancer facilities in S.A. seen as cutting-edge (Video)
07/07/08	ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing
06/03/08	Proteolix Tries Carfilzomib For Relapsed Solid Tumors
06/02/08	Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial
05/31/08	Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
05/28/08	Local Cancer Researcher Sees Benefit from Network Effort
05/12/08	New cancer treatment has promising results (Article)
05/12/08	New cancer treatment has promising results (Video)
05/12/08	Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumor
04/26/08	Curis Announces Dosing of First Patient in Phase I
04/25/08	Jobs in Cancer Medicine
04/21/08	Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
04/16/08	START gains more recognition in cancer-fighting effort
04/16/08	Cyclacel Pharmaceuticals Presents Insights into the Mechanisms of Its Cell Cycle Inhibitor Drugs
03/25/08	Dr. Anthony Tolcher to Speak at the AACR Annual Meeting on Chemokine Therapeutic's Lead Drug
03/13/08	START chosen to test drug compound that suppresses cancer-causing gene
01/30/08	START co-founder accepts position at Johnson & Johnson

4319 Medical Drive, Suite 205
San Antonio, TX 78229

Phone: (210) 593-5250
Fax: (210) 615-1121